Role of staphylococcal enterotoxin A in a fatal case of endocarditis

References

1. Cassada D. C, Moniz M, Stevens S. L, Freeman M. B, Goldman M. H, Schuchmann G. S. 1999; Factors affecting the surgical management of infective endocarditis. Am Surg 65:307–310
   [Google Scholar]
2. Colque-Navarro P, Söderquist B, Holmberg H, Blomqvist L, Olcen P, Möllby R. 1998; Antibody response in Staphylococcus aureus septicaemia –a prospective study. J Med Microbiol 47:217–225 [CrossRef]
   [Google Scholar]
3. Colque-Navarro P, Palma M, Söderquist B, Flock J.-I, Möllby R. 2000; Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: clumping factor and an extracellular fibrinogen binding protein. Clin Diagn Lab Immunol 7:14–20
   [Google Scholar]
4. Dinges M. M, Orwin P. M, Schlievert P. M. 2000; Exotoxins of Staphylococcus aureus . Clin Microbiol Rev 13:16–34 [CrossRef]
   [Google Scholar]
5. Fowler V. G Jr, Li J., Corey G. R. 8 other authors 1997; Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 30:1072–1078 [CrossRef]
   [Google Scholar]
6. Gentry C. A, Rodvold K. A, Novak R. M, Hershow R. C, Naderer O. J. 1997; Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17:990–997
   [Google Scholar]
7. Kanclerski K, Söderquist B, Kjellgren M, Holmberg H, Möllby R. 1996; Serum antibody response to Staphylococcus aureus enterotoxins and TSST-1 in patients with septicaemia. J Med Microbiol 44:171–177 [CrossRef]
   [Google Scholar]
8. Kaul R, McGreer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low D. E. 1999; Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome –a comparative observational study. The Canadian Streptococcal Study Group. . Clin Infect Dis 28:800–807 [CrossRef]
   [Google Scholar]
9. LeClaire R. D, Bavari S. 2001; Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality. Antimicrob Agents Chemother 45:460–463 [CrossRef]
   [Google Scholar]
10. Möllby R. 1983; Isolation and properties of membrane damaging toxins. In Staphylococci and Staphylococcal Infections vol. 2 pp 628–630 Edited by Easmon C. S. F., Adams C. London: Academic Press;
    [Google Scholar]
11. Monday S. R, Bohach G. A. 1999; Properties of Staphylococcus aureus enterotoxins and toxic shock syndrome toxin-1. In The Comprehensive Sourcebook of Bacterial Toxins . , 2nd edn. pp 589–609 Edited by Alouf J. E., Freer J. H. London: Academic Press;
12. Norrby-Teglund A, Basma H, Andersson J, McGreer A, Low D. E, Kotb M. 1998; Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 26:631–638 [CrossRef]
    [Google Scholar]
13. Roder B. L, Wandall D. A, Frimodt-Moller N, Espersen F, Skinhoj P, Rosdahl V. T. 1999; Clinical features of Staphylococcus aureus endocarditis. a 10-year experience in Denmark. Arch Intern Med 159:462–469 [CrossRef]
    [Google Scholar]
14. Watanakunakorn C. 1994; Staphylococcus aureus endocarditis at a community teaching hospital, 1980 to; 1991; An analysis of 106 cases. Arch Intern Med 154:2330–2335 [CrossRef]
    [Google Scholar]
15. Working Party of the British Society for Antimicrobial Chemotherapy; 1998; Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis. Heart 79:207–210 [CrossRef]
    [Google Scholar]